Industry News
Join Christopher Kata, Director of Sales & Marketing, and Nick Travers, Business Development Director, at the SCOPE Summit in Orlando, Florida, from February 2-5, 2025. If you plan to attend, we invite you to connect with Christopher and Nick to schedule a one‑on‑one meeting, or feel free to visit our booth at your convenience. We…
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the COG CRO Summit in Raleigh, North Carolina. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with Chris Hamelin…
Excerpt from the Press Release: HANGZHOU, China and SHANGHAI and BOSTON, Nov. 19, 2025 /PRNewswire/ — Lynk Pharmaceuticals Co., Ltd. (hereinafter referred to as “Lynk Pharmaceuticals”), a clinical-stage innovative drug development company, today announced key results from its Phase II clinical trial of LNK01004, a skin restricted, soft pan-JAK inhibitor, for the treatment of atopic…
– The collaboration will leverage General Proximity’s OmniTAC™ platform to identify and advance next generation induced proximity agents for high value oncology targets. – Induced proximity medicines, powered by the OmniTAC™ platform, enable precise modulation of disease-driving and traditionally undruggable proteins. – General Proximity will identify novel effector-target pairs that can be exploited through induced proximity medicines.…
Excerpt from the Press Release: EMERYVILLE, Calif.–(BUSINESS WIRE)–Eureka Therapeutics, Inc., a clinical-stage biotechnology company developing novel T cell therapies for cancer, today announced the publication of a peer-reviewed study titled “Antibody–Gamma/Delta T Cell Receptors Targeting GPC2 Regress Neuroblastoma with Low Antigen Density” in Cell Reports Medicine. The study, led by researchers at the National Cancer…
Excerpt from the Press Release: NEWTON, Mass.–(BUSINESS WIRE)–ClearB Therapeutics, Inc., a clinical-stage biotechnology company committed to developing therapies to drive functional cure in patients with chronic hepatitis B (CHB) infection, announced that review of the safety data from the sentinel subject supported enrollment for the remainder of the cohort in their Phase 1b clinical study…
Overcoming limitations of traditional assay enables definitive diagnosis, refinement of prognosis and opportunities for optimized treatment Excerpt from the Press Release: CARLSBAD, Calif.–(BUSINESS WIRE)–Arima Genomics, Inc., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced the publication of a study from investigators at Johns Hopkins University showing…
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Precision in Clinical Trials Summit in San Diego, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
The TrialStat team is showcasing their cutting-edge EDC Platform with integrated Medical Imaging Workflow Platform at the Clinical Outsourcing Group Bay Area in San Francisco, CA. This conference provides an exceptional opportunity for in-depth discussions on how our platform is advancing imaging based research and streamlining clinical trial execution for Sponsors and CROs. Meet with…
Excerpt from the Press Release: PHILADELPHIA, Oct. 2, 2025 /PRNewswire/ — Verismo Therapeutics, a clinical-stage CAR T company developing novel KIR-CAR platform technology, today announced that it has treated the first patient with follicular lymphoma (FL) in its CELESTIAL-301 Phase 1 clinical trial of SynKIR™-310. This milestone reflects Verismo’s commitment to addressing the urgent unmet medical…